Medicure Announces Q2 2026 Financial Results and Upcoming Conference Call

Medicure Inc. reported its financial performance for Q2 2026, showing an increase in total net revenue to $7.4 million, up from $6.7 million in the same quarter of 2025. Revenue from ZYPITAMAG® sales rose to $2.1 million, while AGGRASTAT® revenue fell to $661,000 amid generic competition. The pharmacy segment, including Marley Drug and two recently acquired pharmacies, generated $5.9 million in revenue, reflecting strategic growth initiatives.

Adjusted EBITDA turned positive at $172,000, contrasting with a negative $28,000 in 2025, supported by increased revenue from the pharmacy segment and ZYPITAMAG®. However, Medicure posted a net loss of $1.4 million, a rise from the previous year's loss of $786,000, driven by CMS liabilities and amortization expenses.

Despite the challenges, the company allocated $608,000 towards R&D, reinforcing its commitment to advancing treatments such as MC-1 for PNPO deficiency. The financial specifics align with providing long-term value and reflect its resilient operational focus.